Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship
Patrick J. Hensley(University of Kentucky), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Charles C. Guo(The University of Texas MD Anderson Cancer Center), Roberto Contieri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Hui Zhao, Stephen B. Williams(Cedars-Sinai Medical Center), Niyati Lobo(The University of Texas MD Anderson Cancer Center), Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), Zhigang Duan(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Urologic Oncology Seminars and Original Investigations
November 17, 2022
Cited by 4
Related Papers
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k
Acute Hyperglycemia Attenuates Endothelium-Dependent Vasodilation in Humans In Vivo
|Circulation|1998|804
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Epidemiology, Screening, and Prevention of Bladder Cancer
|European Urology Oncology|2022|361